Evidence map›Paper›PMID 41816294›Full record

ArticleiScience2026

Persistent viral control status is associated with enhanced innate immune responses in people with HIV-1.

Jéssica C Dos Santos, Albert L Groenendijk, Suzanne D E Ruijten, Rainer Knoll, Nadira Vadaq, Rob Ter Horst, Ezio T Fok, Wojciech Witkowski, Marc J T Blaauw, Louise E van Eekeren and 20 more

Abstract read
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Early immune responses anticipate HIV rebound and precede viral control.bioRxiv : the preprint server for biology · 2026
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Jéssica C Dos SantosDepartment of Internal Medicine and Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands.
Albert L GroenendijkDepartment of Internal Medicine and Department of Medical Microbiology and Infectious Diseases, ErasmusMC, Erasmus University, Rotterdam, the Netherlands.
Suzanne D E RuijtenDepartment of Internal Medicine and Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands.
Rainer KnollSystems Medicine, Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) eingetragener Verein (e.V.), Bonn, Germany.
Nadira VadaqDepartment of Internal Medicine and Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands.
Rob Ter HorstCenter for Molecular Medicine (CeMM) Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Ezio T FokDepartment of Internal Medicine and Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands.
Wojciech WitkowskiHIV Cure Research Center, Department of Internal Medicine and Pediatrics, Ghent University Hospital, Ghent University, Ghent, Belgium.
Marc J T BlaauwDepartment of Internal Medicine and Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands.
Louise E van EekerenDepartment of Internal Medicine and Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands.
Wilhelm A J W VosDepartment of Internal Medicine and Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands.
Maartje Cleophas-JacobsDepartment of Internal Medicine and Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands.
Stephan ReichlCenter for Molecular Medicine (CeMM) Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Twan OttenDepartment of Internal Medicine and Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands.
Joost H A MartensDepartment of Molecular Biology, Radboud University, Nijmegen, the Netherlands.
Arnold van der MeerDepartment of Laboratory Medicine, Laboratory of Medical Immunology, Radboud Medical Center, Nijmegen, the Netherlands.
Han KoninkxDepartment of Laboratory Medicine, Laboratory of Medical Immunology, Radboud Medical Center, Nijmegen, the Netherlands.
Marien I de JongeDepartment of Laboratory Medicine, Laboratory of Medical Immunology, Radboud Medical Center, Nijmegen, the Netherlands.
Marc D BeyerImmunogenomics & Neurodegeneration, Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) (e.V.), Bonn, Germany.
Jan van LunzenDepartment of Internal Medicine and Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands.
Leo A B JoostenDepartment of Internal Medicine and Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands.
Christoph BockCenter for Molecular Medicine (CeMM) Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Casper RokxDepartment of Internal Medicine and Department of Medical Microbiology and Infectious Diseases, ErasmusMC, Erasmus University, Rotterdam, the Netherlands.
Annelies VerbonDepartment of Internal Medicine and Department of Medical Microbiology and Infectious Diseases, ErasmusMC, Erasmus University, Rotterdam, the Netherlands.
Linos VandekerckhoveHIV Cure Research Center, Department of Internal Medicine and Pediatrics, Ghent University Hospital, Ghent University, Ghent, Belgium.
Anna C AschenbrennerSystems Medicine, Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) eingetragener Verein (e.V.), Bonn, Germany.
Joachim L SchultzeSystems Medicine, Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) eingetragener Verein (e.V.), Bonn, Germany.
Vasiliki MatzarakiDepartment of Internal Medicine and Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands.
Andre J A M van der VenDepartment of Internal Medicine and Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands.
Mihai G NeteaDepartment of Internal Medicine and Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mechanisms mediating elite and persistent HIV control in people living with HIV (PLHIV) are only partially understood and largely attributed to adaptive T cell responses, but whether innate immunity also contributes remains unclear. Using samples from the 2000HIV study, we examined the transcriptional and functional profiles of monocytes from spontaneous HIV controllers and normal progressors on long-term antiretroviral therapy. HIV controllers displayed enhanced cytokine production after bacterial and viral stimulation, alongside antiviral and interferon-inducible transcriptional signatures and reduced inflammatory gene expression. Persistent controllers further showed increased capacity for trained immunity, with H3K4me3 profiling indicating the epigenetic priming of innate immune genes. Remarkably, relatives of persistent controllers also exhibited stronger innate and trained immune responses than relatives of normal progressors. These findings suggest that robust innate immunity, particularly monocyte function, may precede infection and contribute to sustained HIV control, offering new avenues for therapies that induce similar innate antiviral responses.

Indexed as

Clinical findingDiseaseHealth sciencesImmunologyMedicine

Identifiers

PMID41816294
PMCPMC12973709

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.